Brought to you by 
Migraine drug developer CoLucid nets $51.2mm in IPO
08 May 2015
Executive Summary
CoLucid Pharmaceuticals Inc. (migraine) netted $51.2mm in its initial public offering of 5.5mm shares--slightly above the 5.36mm it planned--at $10, below its $13-15 range. Entities affiliated with the company's existing investors indicated they might buy $25mm in IPO shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Migraine drug developer CoLucid nets $51.2mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice